Novel Fidaxomicin Treatment Regimens for Patients With Multiple Clostridium difficile Infection Recurrences That Are Refractory to Standard Therapies

Treatment approaches including fecal microbiota transplantation for recurrent Clostridium difficile infection (RCDI) among infectious disease physicians

(2013) Johan S. Bakken et al.   ANAEROBE

Successful use of fidaxomicin in recurrent Clostridium difficile infection in a child

(2013) S. Smeltzer et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile

(2013) Els van Nood et al.   NEW ENGLAND JOURNAL OF MEDICINE

Defining the Vulnerable Period for Re-Establishment of Clostridium difficile Colonization after Treatment of C. difficile Infection with Oral Vancomycin or Metronidazole

(2013) Turki Abujamel et al.   PLoS One

Fidaxomicin Failures in Recurrent Clostridium difficile Infection: A Problem of Timing

(2012) R. Orenstein   CLINICAL INFECTIOUS DISEASES

Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI

(2012) T. J. Louie et al.   CLINICAL INFECTIOUS DISEASES

Fidaxomicin "Chaser" Regimen Following Vancomycin for Patients With Multiple Clostridium difficile Recurrences

(2012) S. Johnson et al.   CLINICAL INFECTIOUS DISEASES

Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin

(2012) O. A. Cornely et al.   CLINICAL INFECTIOUS DISEASES

Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance

(2012) Robert A. Britton et al.   TRENDS IN MICROBIOLOGY

Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections

(2011) Kathleen M. Mullane et al.   CLINICAL INFECTIOUS DISEASES

A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection

(2011) K. W. Garey et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Fidaxomicin versus Vancomycin forClostridium difficileInfection

(2011) Thomas J. Louie et al.   NEW ENGLAND JOURNAL OF MEDICINE

A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin

(2010) G. W. Tannock et al.   MICROBIOLOGY-SGM

Treatment with Monoclonal Antibodies againstClostridium difficileToxins

(2010) Israel Lowy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rifaximin Redux: Treatment of recurrent Clostridium difficile infections with Rifaximin immediately post-vancomycin treatment

(2009) Stuart Johnson et al.   ANAEROBE

Decreased Diversity of the Fecal Microbiome in RecurrentClostridium difficile–Associated Diarrhea

(2008) Ju Young Chang et al.   JOURNAL OF INFECTIOUS DISEASES